Sapient Capital LLC Purchases 3,559 Shares of Ascendis Pharma A/S $ASND

Posted by Stanley Muller on Oct 8th, 2026

Sapient Capital LLC raised its position in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 3.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 95,721 shares of the biotechnology company’s stock after acquiring an additional 3,559 shares during the quarter. Sapient Capital LLC owned approximately 0.15% of Ascendis Pharma A/S worth $21,808,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Personal CFO Solutions LLC raised its holdings in shares of Ascendis Pharma A/S by 4.4% in the 1st quarter. Personal CFO Solutions LLC now owns 1,519 shares of the biotechnology company’s stock valued at $347,000 after purchasing an additional 64 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 69 shares during the last quarter. Allworth Financial LP raised its position in shares of Ascendis Pharma A/S by 103.4% during the 2nd quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 122 shares in the last quarter. Kennedy Capital Management LLC lifted its stake in Ascendis Pharma A/S by 0.6% during the fourth quarter. Kennedy Capital Management LLC now owns 19,862 shares of the biotechnology company’s stock worth $4,235,000 after purchasing an additional 123 shares during the last quarter. Finally, Parallel Advisors LLC boosted its holdings in Ascendis Pharma A/S by 94.9% in the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 148 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Oppenheimer raised their price objective on shares of Ascendis Pharma A/S from $304.00 to $312.00 and gave the stock an “outperform” rating in a report on Tuesday, September 1st. Stifel Nicolaus dropped their target price on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating on the stock in a research report on Monday, August 31st. Royal Bank Of Canada lifted their price target on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the stock an “outperform” rating in a research note on Friday, August 14th. Wall Street Zen downgraded shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday, September 26th. Finally, Bank of America dropped their price objective on Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating on the stock in a report on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $310.75.

Read Our Latest Report on Ascendis Pharma A/S

Insider Activity at Ascendis Pharma A/S

In other news, Director Jean-Jacques Bienaimé acquired 2,000 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the transaction, the director directly owned 2,900 shares in the company, valued at approximately $714,357. This represents a 222.22% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Mads Bodenhoff sold 3,000 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the transaction, the senior vice president owned 3,000 shares of the company’s stock, valued at approximately $810,570. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Stock Performance

ASND stock traded down $5.72 on Thursday, hitting $222.69. The company’s stock had a trading volume of 924,127 shares, compared to its average volume of 704,306. Ascendis Pharma A/S has a 1 year low of $186.05 and a 1 year high of $282.15. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. The stock has a market cap of $13.89 billion, a price-to-earnings ratio of 17.28 and a beta of 0.38. The firm has a 50 day moving average of $247.48 and a two-hundred day moving average of $242.22.

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last announced its earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The business had revenue of $387.22 million during the quarter, compared to analysts’ expectations of $376.75 million. Equities analysts predict that Ascendis Pharma A/S will post 3.55 EPS for the current fiscal year.

About Ascendis Pharma A/S

(Free Report)

Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapies for rare diseases, particularly in endocrinology. The company uses its proprietary TransCon technology platform to design medicines intended to provide sustained release of therapeutic compounds and potentially improve treatment convenience and patient outcomes.

Ascendis Pharma’s marketed products include Skytrofa (lonapegsomatropin-tcgb), a once-weekly growth hormone treatment for children with growth hormone deficiency, and Yorvipath (palopegteriparatide), a parathyroid hormone replacement therapy for adults with hypoparathyroidism.